abrdn plc Acquires Shares of 146,829 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

abrdn plc acquired a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 146,829 shares of the biotechnology company’s stock, valued at approximately $14,159,000. abrdn plc owned approximately 0.16% of Sarepta Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SRPT. Montag A & Associates Inc. purchased a new stake in shares of Sarepta Therapeutics during the third quarter worth about $30,000. Cary Street Partners Investment Advisory LLC increased its stake in shares of Sarepta Therapeutics by 154.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 154 shares in the last quarter. Fifth Third Bancorp increased its stake in shares of Sarepta Therapeutics by 1,215.8% during the fourth quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 924 shares in the last quarter. Hudson Capital Management LLC purchased a new stake in shares of Sarepta Therapeutics during the third quarter worth about $206,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Sarepta Therapeutics by 96.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,397 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 1,176 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Wedbush reissued an “outperform” rating and set a $224.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Evercore ISI upped their price objective on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research note on Tuesday, February 20th. Royal Bank of Canada upped their price objective on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a research note on Thursday, February 29th. UBS Group upped their price objective on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Citigroup upped their price objective on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $158.38.

Insider Transactions at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.30, for a total value of $153,960.00. Following the transaction, the chief financial officer now directly owns 39,114 shares in the company, valued at approximately $5,018,326.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.84, for a total transaction of $257,680.00. Following the sale, the insider now directly owns 26,836 shares in the company, valued at approximately $3,457,550.24. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Ian Michael Estepan sold 1,200 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the sale, the chief financial officer now owns 39,114 shares in the company, valued at $5,018,326.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,096 shares of company stock worth $2,739,419. 7.40% of the stock is currently owned by insiders.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $127.39 on Friday. The firm’s 50 day moving average price is $126.22 and its 200-day moving average price is $110.43. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95. Sarepta Therapeutics, Inc. has a one year low of $55.25 and a one year high of $159.89. The firm has a market cap of $11.96 billion, a P/E ratio of -20.82 and a beta of 0.94.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The firm had revenue of $396.80 million for the quarter, compared to analyst estimates of $387.18 million. During the same period in the prior year, the business posted ($1.24) EPS. The business’s revenue for the quarter was up 53.6% compared to the same quarter last year. As a group, equities research analysts predict that Sarepta Therapeutics, Inc. will post 2.13 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.